The resubmission of Clearside Biomedical’s new drug application for Xipere has been delayed, the company said in a press release.
Clearside said the contract manufacturing organization for Xipere (triamcinolone acetonide suprachoroidal injectable suspension), a potential treatment for macular edema associated with uveitis, is undergoing requalification activities in its facility, and even though the activities are not related to Xipere, they are affecting its production timing. In addition, challenges related to the COVID-19 pandemic have affected work schedules. The NDA is now expected
Uncategorized